112 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private … broad access to Auryxia; and Akebia's goals, objectives and expectations with respect to its operating plan, expenses, cash resources and sources
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include
8-K
EX-99.1
mv1i7dbw ar
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
z66r0zcp6xaie9rj
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
EX-99.1
2nlfak fa
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
uoob12s nhq3
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
EX-99.1
f4gwq7vhso7oiak6swqg
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
EX-99.1
h1owkwkbas
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
tmxtb83d
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
EX-99.1
5hadujr9c fh
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
EX-99.1
l97zioo nmz8upj
11 Aug 23
Akebia Therapeutics Provides Update on Form 10-Q Filing
7:35am
8-K
EX-99.1
hlbnslczk ktwke6x
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am
8-K
EX-99.1
0gyjqk080k
7 Jun 23
Regulation FD Disclosure
7:31am